Longeveron executives to speak at cardiovascular clinical trials forum

Longeveron Inc. (NASDAQ: LGVN) announced that two of its senior executives will participate as speakers at the Global CardioVascular Clinical Trialists Forum scheduled for December 8-10 in Washington, D.C.

Chief Science Officer Dr. Joshua Hare will present on two panel discussions December 8 focused on cell therapy for heart failure trials. His presentations will cover intravenous delivery of cell products and mesenchymal stem cell therapy for dilated cardiomyopathy, drawing from the company's POSEIDON study experience.

Chief Medical Officer Dr. Nataliya Agafonova will serve as a panelist in a discussion about streamlining cell therapy innovation while maintaining evidence standards.

Longeveron is a clinical-stage biotechnology company developing cellular therapies for pediatric and aging-related conditions. The company's primary investigational product is laromestrocel, an allogeneic mesenchymal stem cell therapy derived from bone marrow of young adult donors.

The company is pursuing three pipeline indications: hypoplastic left heart syndrome, Alzheimer's disease, and pediatric dilated cardiomyopathy. Laromestrocel has received five FDA designations across these programs, including Orphan Drug designation, Fast Track designation, Rare Pediatric Disease designation, and Regenerative Medicine Advanced Therapy designation.

The information is based on a company press release statement.

You May Also Be Interested In

• Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update
• Synchrony names former Citi executive as chief AI officer
• OpenAI names Dali Rajic as Chief Revenue Officer